Standard or Bespoke: How an Orthopaedic Implant Manufacturer Used Bespoke Research and Strategy Advisory to Decide Between Patient-Specific and Catalogue 3D Printing

Three-dimensional printing has opened genuinely new clinical possibilities in orthopaedic implantology, particularly for revision surgeries, complex anatomical cases, and patients whose bone stock does not accommodate standard implant sizes. The technology enables geometries and surface structures that conventional manufacturing cannot produce, and the clinical evidence for patient-specific implants in specific indication categories is becoming increasingly robust.

The client had arrived at an investment decision point without having answered that question rigorously. The clinical team was strongly drawn to the patient-specific model on scientific grounds.

Making the wrong choice at this investment stage would not merely delay returns, it would commit engineering, regulatory, and commercial resources to a model that either the payer environment or the regulatory pathway made uneconomic for years before that conclusion became visible in revenue data.

Key Challenges

• No independent research into the actual per-device regulatory cost and approval timeline for patient-specific additive implant submissions in the client’s target markets.
• No bespoke analysis of whether the price premium required to make patient-specific implant economics viable was consistently achievable from NHS and European payer systems.
• No structured assessment of surgeon adoption dynamics for each model, and whether the clinical and practical advantages of patient-specific devices were compelling enough to justify their premium in routine surgical practice.
• A contested set of financial model assumptions that the clinical and commercial teams were unable to resolve from internal evidence alone.
• A board requiring a single, definitive strategic recommendation rather than a presentation of two internally contested options.
• An investment decision that would commit engineering, regulatory, and commercial resources for a decade based on whichever model was chosen.

In medical device markets shaped by public payer systems, the clinical superiority of a device and the commercial viability of the business model behind it are not the same question. A device can be clinically compelling and commercially unviable simultaneously if the regulatory cost structure and payer pricing expectations do not support the unit economics the business model requires.